Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05079698
What this trial is testing

Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Prostate Cancer

Who this might be right for
Prostate Cancer
Memorial Sloan Kettering Cancer Center 29
Not applicableLooking for participantsNCT04983095
What this trial is testing

Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer MetastaticRadiation TherapyPositron-Emission Tomography
Karin Soderkvist 118
Not applicableLooking for participantsNCT07451002
What this trial is testing

Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who this might be right for
Prostatic NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Cilag S.A.S. 540
Post-approval studies (Phase 4)Study completedNCT00035997
What this trial is testing

Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 261
Large-scale testing (Phase 3)Not Yet RecruitingNCT07711002
What this trial is testing

Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
AstraZeneca 1,330
Not applicableStudy completedNCT01233557
What this trial is testing

Biomarkers of Bone Resorption in Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
University of Aberdeen 40
Not applicableStudy completedNCT06452212
What this trial is testing

Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Astellas Pharma Korea, Inc. 23
Not applicableWithdrawnNCT05245435
What this trial is testing

Diagnostic and Prognostic Accuracy of FDHT-PET and Liquid Biopsies in Prostate Cancer

Who this might be right for
Prostate Cancer
Medical University of Vienna
Large-scale testing (Phase 3)Active Not RecruitingNCT05288166
What this trial is testing

Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Who this might be right for
Prostatic NeoplasmsNeoplasm MetastasisUrogenital Neoplasms+14 more
Eli Lilly and Company 925
Testing effectiveness (Phase 2)WithdrawnNCT03343977
What this trial is testing

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Peng Wang, MD PhD
Post-approval studies (Phase 4)Not Yet RecruitingNCT06660862
What this trial is testing

Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Who this might be right for
Prostate Cancer
University of Chicago 80
Testing effectiveness (Phase 2)Ended earlyNCT03533946
What this trial is testing

Rucaparib in Nonmetastatic prOstAte With BRCAness

Who this might be right for
Prostate Cancer
University of Utah 7
Not applicableActive Not RecruitingNCT07766486
What this trial is testing

Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy

Who this might be right for
Oligometastatic Hormone-Sensitive Prostate CancerProstate Adenocarcinoma
Fondazione del Piemonte per l'Oncologia 30
Early research (Phase 1)Looking for participantsNCT07824349
What this trial is testing

JUR-003 in Adult Patients With Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration Resistant Prostate CancerOligometastatic Prostate Cancer (OMPC)Metastatic Hormone Sensitive Prostate Cancer
Juri Biosciences, Inc. 210
Testing effectiveness (Phase 2)Study completedNCT06312670
What this trial is testing

Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Prostate CancerProstate Adenocarcinoma
Pedro Barata, MD, MSc 13
Testing effectiveness (Phase 2)Study completedNCT03934840
What this trial is testing

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Who this might be right for
Prostate Cancer
Masonic Cancer Center, University of Minnesota 61
Testing effectiveness (Phase 2)Study completedNCT04443062
What this trial is testing

Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
Radboud University Medical Center 58
Testing effectiveness (Phase 2)UnknownNCT04641078
What this trial is testing

Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer

Who this might be right for
Prostate CancerProstate Cancer RecurrentProstate Cancer Metastatic+2 more
University Hospital, Ghent 124
Not applicableLooking for participantsNCT06429813
What this trial is testing

Remotely Monitored Exercise Interventions in Patients With mCSPC Undergoing ADT (Prostate 006)

Who this might be right for
Castrate Sensitive Prostate CancerMetastatic Prostate Cancer
Paul Viscuse 24
Very early researchActive Not RecruitingNCT05683964
What this trial is testing

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

Who this might be right for
Prostate AdenocarcinomaProstate CancerMetastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Beth Israel Deaconess Medical Center 9
Next Page